Vimarsana
Biggest News Aggregation in the World

Javier Cortes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Javier Cortes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Javier Cortes Today - Breaking & Trending Today

Richard Kellen - Vimarsana News

Richard Kellen

Richard L. Kellen, 77, of Aurora, passed away Thursday, February 5, 2015 at his home surrounded by his loving family. He was born September 6, 1937 in Auror

Drug breakthrough could benefit those with common breast cancer - Vimarsana News

Drug breakthrough could benefit those with common breast cancer

Treating patients who have a common form of breast cancer with immunotherapy, as well as chemotherapy, before and after surgery could be effective...

De-Escalation of Therapy Remains a Focus for Early-Stage HER2+ Breast Cancer - Vimarsana News

De-Escalation of Therapy Remains a Focus for Early-Stage HER2+ Breast Cancer

Francisco Javier Esteva, MD, PhD, discusses the management of early-stage HER2-positive breast cancer with a focus on de-escalation strategies, emphasizes the ongoing efforts to de-escalate chemotherapy without compromising effective treatments, and expands on the ongoing debate regarding the role of carboplatin in this setting.

Payer Perspectives on SERDs - Vimarsana News

Payer Perspectives on SERDs

Dr Langer explores how payers think about the authorization process for DEXA scans and other surveillance activities that would be required for selective estrogen receptor degraders (SERDs) and how oral SERDs affect quality of life.

Source: ajmc.com
Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer - Vimarsana News

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer

The European Commission has approved sacituzumab govitecan-hziy for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the advanced setting